Who is sponsoring NCT02170662?

NCT02170662 is sponsored by Duke University.

What condition does NCT02170662 study?

NCT02170662 studies Male Pattern Hair Loss, Androgenetic Alopecia.

What drugs are being tested in NCT02170662?

Interventions: Bimatoprost, Placebo.

What is the status of NCT02170662?

NCT02170662 is currently COMPLETED.

Last reviewed 2014-08-27 · How we verify

Topical Bimatoprost Effect on Androgen Dependent Hair Follicles

NCT02170662 Phase 2 COMPLETED Results posted

The purpose of this study is to determine the effect of bimatoprost solution on scalp hair growth. Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment of glaucoma (Lumigan™) and for thickening of thin eyelashes (Latisse™). Bimatoprost 0.03% is not approved for the treatment of scalp hair loss and its use in this study is considered investigational which means it is still being tested in research studies. Thirty-three subjects were consented and screened, 9 entered and 9 completed the study.

Details

Lead sponsor	Duke University
Phase	Phase 2
Status	COMPLETED
Enrolment	33
Start date	2009-11
Completion	2011-05

Conditions

Male Pattern Hair Loss
Androgenetic Alopecia

Interventions

Bimatoprost
Placebo

Primary outcomes

Percent Change in Target Area Total Hair Count — Baseline to week 17; and week 17 to week 34
The primary endpoint is the percent change in total hair count from the beginning and end of each part of the study.